11. Sacubitril-valsartan improves radial and longitudinal strain and ejection fraction in C57Bl/6 mice treated with doxorubicin through NLRP3 mediated pathways and reduction of cytokine storm. (4th February 2022) Authors: Quagliariello, V; Buccolo, S; Iovine, M; Maurea, C; Rea, D; Barbieri, A; Maurea, N Journal: European heart journal Issue: Volume 23(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) improves ejection fraction and longitudinal strain in mice treated with doxorubicin through NLRP3. (14th October 2021) Authors: Quagliariello, V; Bonelli, A; Paccone, A; Buccolo, S; Iovine, M; Rea, D; Cerrone, F; Botti, G; Maurea, N Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. TheSGLT-2 inhibitor dapagliflozin ehnanced the anticancer activities and exerts cardioprotective effects during exposure to ipilimumab through NLRP3 inflammasome and pro-fibrotic cytokines. (14th October 2021) Authors: Maurea, N; Quagliariello, V; Bonelli, A; Paccone, A; Conforti, G; Caronna, A; Buccolo, S; Iovine, M; Cerrone, F; Botti, G Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗